Similar Papers

Paper Title
Journal
Date
Author
Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance
S Boonen ... K Venken
Journal of Internal Medicine | VOL. 264
S Boonen, et. al.S Boonen ... K Venken
10 Sep 2008
Tolerability of the first infusion of once-yearly zoledronic acid within one to two weeks after hip fracture surgery.
Masafumi Kashii ... Takashi Kamatani
Bone | VOL. 155
Masafumi Kashii, et. al.Masafumi Kashii ... Takashi Kamatani
01 Feb 2022
SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
Moe Wint Aung ... Zar Chi Pyone
Journal of the Endocrine Society | VOL. 4
Moe Wint Aung, et. al.Moe Wint Aung ... Zar Chi Pyone
08 May 2020
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Dennis M Black ...
New England Journal of Medicine | VOL. 356
Dennis M Black, et. al.Dennis M Black ...
03 May 2007
View more papers

More From: Neuromuscular Disorders

Paper Title
Journal
Date
Author
CMT2 and distal hereditary motor neuropathy associated with VRK1 variants: case series
Sasha A Živković ... Daniel Dicapua
Neuromuscular Disorders | VOL. 47
Sasha A Živković, et. al.Sasha A Živković ... Daniel Dicapua
01 Feb 2025
Bone Mineral Density Changes in Patients on Drug Therapy for Spinal Muscular Atrophy
Abdelrahman Osman ... Eileen Broomall
Neuromuscular Disorders | VOL. -
Abdelrahman Osman, et. al.Abdelrahman Osman ... Eileen Broomall
01 Feb 2025
Motor Function Testing Rates and Outcomes in Duchenne Muscular Dystrophy with Comorbid Autism and Attention-Deficit/Hyperactivity Disorder
Dennis Keselman ... Susan E Matesanz
Neuromuscular Disorders | VOL. -
Dennis Keselman, et. al.Dennis Keselman ... Susan E Matesanz
01 Jan 2025
MRC CENTRE NEUROMUSCULAR DISEASE BIOBANK LONDON: ITS ROLE IN THE ADVANCEMENT OF RARE AND NEUROMUSCULAR DISEASES RESEARCH
Pierpaolo Ala ... Jennifer Morgan
Neuromuscular Disorders | VOL. -
Pierpaolo Ala, et. al.Pierpaolo Ala ... Jennifer Morgan
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.